Shared on 13 Oct 25
Everest Medicines' analyst price target has been adjusted downward from $29.16 to $26.79, reflecting analysts' moderated growth and profitability expectations in light of updated risk assessments. What's in the News Everest Medicines provided earning guidance for the full year 2025, projecting revenue of RMB 1.6 billion to RMB 1.8 billion, with RMB 1.2 billion to RMB 1.4 billion expected from NEFECON sales (Key Developments).
Shared on 29 Sep 25
Fair value Increased 3.02%Driven by a meaningful improvement in net profit margin and a notable drop in future P/E, analysts have modestly raised Everest Medicines’ fair value, with the consensus price target increasing from HK$62.67 to HK$64.56. What's in the News Everest Medicines expects full-year 2025 revenue of RMB 1.6–1.8 billion, with RMB 1.2–1.4 billion from NEFECON sales.
Shared on 14 Sep 25
Fair value Increased 2.14%The recent upward revision in Everest Medicines’ consensus Analyst Price Target is primarily driven by a modest increase in its expected future P/E multiple, lifting fair value from HK$61.36 to HK$62.67. What's in the News Everest Medicines expects 2025 revenue of RMB 1.6–1.8 billion, with NEFECON sales contributing RMB 1.2–1.4 billion.
Shared on 31 Aug 25
Fair value Increased 11%The notable increase in Everest Medicines’ consensus price target reflects a significant improvement in net profit margin alongside a sharp decline in future P/E, indicating enhanced profitability and a more attractive valuation, with the target rising to HK$57.29. What's in the News The board will meet to discuss interim results for the first half of 2025 and other business.